03 May '12, 4am
China Animal – can biological drugs growth stem the share price decline?
, FY11 revenue and net profit rose 30% and 86% year on year (“y/y”) to RMB768m and RMB223m respectively. Excluding the gain in fair value of derivative financial instruments and amortised interest expense relating to the convertible bonds, adjusted net profit would have risen 78% y/y to RMB207m. EPS rose 84% y/y to RMB14.0 cents in FY11. *(I compared against FY10 results because the historical high share price seen in